Аутосомно-доминантная поликистозная болезнь почек взрослых: перспективные подходы к лечению


Обсуждаются перспективы лечения аутосомно-доминантной поликистозной болезни почек взрослых,
в т. ч. основанные на таргетном принципе.

Литература


1. Torres V.E., Harris P.C. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int. 2009; 76: 149–168.
2. Perrone R.D., Ruthazer R., Terrin N.C. Survival after end-stage renal disease in autosomal dominant polycystic kidney disease: contribution of extrarenal complications to mortality. Am. J. Kidney Dis. 2001; 38: 777–784.
3. Parfrey P.S., Barrett B.J. Hypertension in autosomal dominant polycystic kidney disease. Curr. Opin. Nephrol. Hypertens 1995; 4: 460–464.
4. Schrier R.W., Johnson A.M., McFann K., Chapman A.B. The role of parental hypertension in the frequency and age of diagnosis of hypertension in offspring with autosomal-dominant polycystic kidney disease. Kidney Int 2003; 64:1792–1799.
5. Idrizi A., Barbullushi M., Strakosha A. et al. The relation of hypertension, renal function and cardiovascular events in autosomal dominant polycystic kidney disease. G. Ital. Nefrol. 2007; 24: 595–599.
6. Covic A., Mititiuc I., Gusbeth-Tatomir P., Goldsmith D.J. The reproducibility of the circadian BP rhythm in treated hypertensive patients with polycystic kidney disease and mild chronic renal impairment - a prospective ABPM study. J. Nephrol 2002;15: 497–506.
7. Chapman A.B., Johnson A.M., Rainguet S. et al. Left ventricular hypertrophy in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 1997; 8: 1292–1297.
8. Torres V.E., King B.F., Chapman A.B. et al. Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2007; 2: 112–120.
9. Chapman A.B., Johnson A., Gabow P.A., Schrier R.W. The renin-angiotensinaldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med 1990; 323: 1091–1096.
10. Wang D., Iversen J., Wilcox C.S., Strandgaard S. Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease. Kidney Int 2003; 64: 1381–1388.
11. Chapman A.B., Stepniakowski K, Ranbari-Oskoui F. Hypertension in autosomal polycystic kidney disease. Adv. Chronic Kidney Dis. 2010; 17(2): 153–163.
12. Kanno Y., Okada H., Moriwaki K. et al. The effects of antihypertensive agents on the survival rate of polycystic kidney disease in Han:SPRD rats. Hypertens Res. 2002; 25(6): 939–943.
13. Zeltner R., Poliak R., Stiasny B. et al. Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease. Nephrol. Dial. Transplant. 2008; 23(2): 573–579.
14. Maschio G., Alberti D., Janin G. et al. Effect of the angiotensin-convertingenzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996; 334(15): 939–945.
15. Ulusoy S., Ozkan G., Orem C. et al. A comparison of the effects of ramipril and losartan on blood pressure control and left ventricle hypertrophy in patients with autosomal dominant polycystic kidney disease. Ren. Fail. 2010; 32(8): 913–917.
16. Amico P., Kalbermatter S., Kiss D. et al. Aliskiren corrects recurrent hyperreninemia and hyperaldosteronism in autosomal dominant polycystic kidney disease. Clin. Nephrol. 2009; 72(3): 237–239.
17. Chapman A.B. Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD Studies. Clin J Am Soc Nephrol 2008; 3: 1197–1204.
18. Bae K.T., Commean P.K., Lee J. Volumetric measurement of renal cysts and parenchyma using MRI: phantoms and patients with polycystic kidney disease. J Comput Assisted Tomogr 2000; 24: 614–619.
19. Grantham J.J., Torres V.E., Chapman A.B. et al. Volume progressionin polycystic kidney disease. N Engl J Med 2006; 354: 2122–2130.
20. Chapman A.B., Guay-Woodford L., Grantham J.J. et al. Renal structure in early autosomal dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) Cohort. Kidney Int 2003; 64: 1035–1045.
21. Yamaguchi T., Pelling J.C., Ramaswamy N.T. et al. cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int. 2000; 57: 1460–1471.
22. Masyuk A.I., Masyuk T.V., Splinter P.L, et al. Cholangiocyte cilia detect changes in luminal fluid flow and transmit them into intracellular Ca2+ and cAMP signaling. Gastroenterology 2006; 131: 911–920.
23. van Keimpema L., Nevens F., Vanslembrouck R. et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2009; 137(5): 1661-8.e1-2.
24. Hogan M.C., Masyuk T.V., Page L.J. et al. Randomized clinical trial of longacting somatostatin for autosomal dominant polycystic kidney and liver disease. J. Am. Soc. Nephrol. 2010; 21(6): 1052–1061.
25. Meijer E., Boertien W.E., Zietse R., Gansevoort R.T. Potential deleterious effects of vasopressin in chronic kidney disease and particularly autosomal dominant polycystic kidney disease. Kidney Blood Press Res. 2011; 34(4): 235–244.
26. Nagao S., Nishii K., Katsuyama M. et al. Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol 2006;17(8): 2220–2227.
27. Chapman A.B., Torres V.E., Grantham J.J. et al. A phase IIB pilot study for the safety and efficacy of tolvaptan, a vasopressin V2 receptor antagonist (V2RA) in patients with ADPKD. J. Am. Soc. Nephrol 2005; 16: 68A.
28. Zafar I., Tao Y., Falk S. et al. Effect of statin and angiotensin-converting enzyme inhibition on structural and hemodynamic alterations in autosomal dominant polycystic kidney disease model. Am J Physiol Renal Physiol 2007; 293: F854–F859.
29. van Dijk M.A., Kamper A.M., van Veen S. et al. Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2001;16: 2152–2157.
30. Leuenroth S.J., Okuhara D., Shotwell J.D. et al. Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease. Proc Natl Acad Sci USA 2007;104: 4389–4394.
31. Rankin C.A., Itoh Y., Tian C. et al. Matrix metalloproteinase-2 in a murine model of infantile-type polycystic kidney disease. J. Am. Soc. Nephrol. 1999; 10(2): 210–217.
32. Obermuller N., Morente N., Kranzlin B. et al. A possible role for metalloproteinases in renal cyst development. Am J Physiol Renal Physiol 2001; 280(3): F540–F550.
33. Sweeney W.E. Jr., Hamahira K., Sweeney J. et al. Combination treatment of PKD utilizing dual inhibition of EGF-receptor activity and ligand bioavailability. Kidney Int. 2003; 64: 1310–1319.
34. Serra A.L., Poster D., Kistler A.D. et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med. 2010; 363(9): 820–829.


Похожие статьи


Бионика Медиа